Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 avr. 2025 16h00 HE | Source: Interpace Biosciences, Inc.

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace”...
29 juil. 2024 08h25 HE | Source: Interpace Biosciences, Inc.

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined...
30 avr. 2020 08h32 HE | Source: CMI

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market to surpass US$ 211.3 Mn globally by 2027, Says CMI

SEATTLE, April 30, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global methicillin resistant Staphylococcus aureus (MRSA) testing systems market is estimated to be valued at...